Please assess the completion status of the following clinical trial:

Trial Title: Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Confirmed diagnosis of one of the following:~  * Primary acute myeloid leukemia (AML) meeting any of the following criteria:~    * First complete remission (CR; defined as \< 5% blasts in marrow) with high-risk features as defined by failure to achieve remission by day 21 after induction chemotherapy, or the presence of chromosomal abnormalities involving any of the following:~      * -5/del(5q)~     * -7/del(7q)~     * Inversion 3q~     * Abnormalities of 11q23, 20q, 21q, del(9q),~     * Translocation 6;9~     * Translocation 9;22~     * Abnormalities of 17p~     * Complex karyotype with ≥ 3 abnormalities~   * Second CR or subsequent in remission~   * Refractory or relapsed disease~ * Secondary AML in remission or relapse~ * Chronic myelogenous leukemia (CML) in accelerated or blast phase meeting the following criteria:~    * Accelerated phase is defined by any one of the following:~      * Blasts 10% to 19% of peripheral blood white cells or bone marrow cells~     * Peripheral blood basophils ≥ 20%~     * Persistent thrombocytopenia (\< 100,000/mm³) unrelated to therapy, or persistent thrombocytosis (\> 1,000,000/mm³) unresponsive to therapy~     * Increasing spleen size and increasing WBC count unresponsive to therapy~     * Cytogenetic evidence of clonal evolution (i.e., the appearance of an additional genetic abnormality that was not present in the initial specimen at the time of diagnosis of chronic phase CML)~   * Blast phase is defined by any of the following:~      * Blasts ≥ 20% of peripheral blood white cells or bone marrow cells~     * Extramedullary blast proliferation~     * Large foci or clusters of blasts in bone marrow biopsy~ * Primary myelodysplastic syndromes (MDS) with an IPSS score \> 1.5~ * Secondary MDS with any IPSS score~ * Primary acute lymphoblastic leukemia meeting any of the following criteria:~    * First CR (\< 5% blasts in marrow) with high-risk features as defined by 1 of the following:~      * Failure to achieve remission after first induction chemotherapy~     * Presence of chromosomal abnormalities including hypodiploidy or abnormalities of 11q23 or translocation 9;22~   * Second CR or subsequent in remission~   * Refractory or relapsed disease~* No patients for whom a suitable HLA genotypically identical sibling or fully matched HLA-A, -B, -C, and -DRB1 unrelated donor is available~* No active CNS involvement with disease~* Donors must meet the following criteria:~  * Unrelated volunteer donors who are mismatched for more than one HLA-class I alleles or antigens or for one HLA-class I antigen, but matched by high-resolution typing at HLA-DRB1 and -DQB1, OR who are mismatched for one or more HLA-class II alleles or antigens, but matched by high-resolution typing at HLA-A, -B, and -C~    * No two-antigen mismatch at a single HLA-A, -B, or -C locus~   * No mismatching of class I and class II HLA~   * Matching must be based on results of high-resolution typing at HLA-A, -B, -C, - DRB1, and -DQB1~PATIENT CHARACTERISTICS:~* Karnofsky performance status 50-100%~* No symptomatic coronary artery disease or symptomatic congestive heart failure~* No hepatic disease with transaminases or bilirubin \> 2 times upper limit of normal except for isolated hyperbilirubinemia attributed to Gilbert's syndrome~* No severe hypoxemia with room air P_AO_2 \< 70, supplemental oxygen-dependence, or DLCO \< 60% predicted~* No impaired renal function with creatinine \> 2 times upper limit of normal or creatinine clearance \< 50% normal~* Not HIV seropositive~* Not pregnant or breast-feeding~* Fertile patients must use effective contraception~* No active infections that are untreated or failing to respond to appropriate therapy~PRIOR CONCURRENT THERAPY:~Inclusion criteria:~* See Disease Characteristics~Exclusion criteria:~* Prior allogeneic or autologous bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation using a high-dose total-body irradiation regimen

- Gender: ALL
- Minimum Age: None
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Alemtuzumab (Type: EXPERIMENTAL): Alemtuzumab given together with busulfan and cyclophosphamide followed by a donor stem cell transplant.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues